New PET tracer aims to sharpen view of HER2 cancers
NCT ID NCT06828588
First seen Oct 31, 2025 · Last updated May 01, 2026 · Updated 16 times
Summary
This early-phase study will test a radioactive tracer called [68Ga]Ga-ABY-025 during PET scans to see if it can better identify HER2-positive tumors in people with advanced or metastatic cancer. About 30 adults who are already receiving standard HER2-targeted therapy will receive the tracer and be monitored for side effects. The goal is to improve imaging of these cancers, not to treat them directly.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Vanderbilt University Medical Center
Nashville, Tennessee, 37232, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.